Cidara Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases that are inadequately addressed by current standard-of-care therapies. Their innovative approach includes their proprietary Cloudbreak® platform, designed to create drug-Fc conjugates (DFCs) that deliver potent antimicrobials directly to the site of infection while also engaging the patient's immune system. Cidara's lead antifungal candidate, rezafungin (REZZAYO™), has received marketing authorization in the U.S. and Europe for the treatment of candidemia and invasive candidiasis. They are also advancing CD388, a DFC, for the universal prevention of influenza A and B in collaboration with Janssen Pharmaceuticals.
The San Diego headquarters serves as the company's primary center for research and development, clinical operations, and corporate and administrative functions.
The facility is situated in Sorrento Valley, a key biotech cluster, and is equipped with modern laboratory spaces for drug discovery and development, alongside collaborative office environments designed to foster scientific innovation.
Cidara Therapeutics cultivates a dynamic, science-driven, and innovative work culture. The environment emphasizes collaboration, scientific rigor, and a strong mission to address critical unmet medical needs in infectious diseases, reflecting the passionate and dedicated nature typical of the San Diego biotech ecosystem.
Its location in San Diego provides Cidara with crucial access to a rich talent pool of scientists and biotech professionals, renowned research institutions, and a supportive ecosystem of suppliers and partners, essential for a company at the forefront of drug development.
While Cidara Therapeutics is headquartered in the United States, its impact and operations are global. The company conducts international clinical trials for its product candidates. Furthermore, Cidara has established strategic partnerships for the commercialization of its products outside the U.S., such as with Mundipharma for rezafungin in ex-U.S. and ex-Japan territories, and a collaboration with Janssen (part of Johnson & Johnson) for the global development of CD388 for influenza. This global approach ensures their novel anti-infectives can reach patients worldwide.
6310 Nancy Ridge Drive, Suite 101
San Diego
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cidara Therapeutics' leadership includes:
Cidara Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12 months, Cidara Therapeutics has experienced significant executive transitions, including the appointment of James Levine as new CFO in August 2023, the promotion of Dr. Lesley Ann Shaw to CSO in December 2023, and the departure of COO Paul Daruwala in January 2024.
Discover the tools Cidara Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cidara Therapeutics appears to primarily use the email format of the employee's first initial followed by their last name, all preceding '@cidara.com'. This is a common structure for corporate email addresses.
firstinitiallastname@cidara.com
Format
jstein@cidara.com
Example
85%
Success rate
GlobeNewswire via Cidara IR • May 9, 2024
Cidara announced its Q1 2024 financial results, highlighting progress in its pipeline, including CD388 (influenza prevention) development with Janssen and ongoing commercialization efforts for REZZAYO™ (rezafungin)....more
GlobeNewswire via Cidara IR • December 22, 2023
The European Commission granted marketing authorization for REZZAYO™ (rezafungin) for treating invasive candidiasis in adults, a significant step for Cidara and its partner Mundipharma in providing a new once-weekly antifungal....more
GlobeNewswire via Cidara IR • December 4, 2023
Cidara announced the promotion of Lesley Ann Shaw, Ph.D., to Chief Scientific Officer. Dr. Shaw previously served as Senior Vice President, Drug Discovery and Site Head....more
GlobeNewswire via Cidara IR • August 8, 2023
Cidara Therapeutics announced the appointment of James (Jamie) Levine as its Chief Financial Officer, effective August 14, 2023, succeeding Preethi Gopinath....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cidara Therapeutics, are just a search away.